Skip to main content
. 2019 May 13;3(9):1540–1545. doi: 10.1182/bloodadvances.2019000090

Table 2.

Genetic features of NPM1 MN, NPM1+ MN, and NPM1+ AML cohorts

NPM1 MN (n = 95) NPM1+ MN (n = 45) NPM1+ AML (n = 119)
Comutations, by pathway, n (%)
 DNMT3A 14 (15)* 15 (33) 57 (48)
 IDH1 22 (2) 4 (9)* 25 (21)*
 IDH2 5 (5) 2 (4)* 16 (13)*
 TET2 29 (31) 7 (16) 32 (27)
 ASXL1 30 (32)* 4 (9) 3 (3)
 RUNX1 20 (21)* 0 (0) 1 (0.8)
 KRAS 3 (3) 1 (2) 4 (3)
 NRAS 8 (8) 4 (9) 27 (23)
 FLT3 (non-ITD) 1 (1) 3 (7) 29 (24)
 FLT3-ITD 1 (1) 1 (2) 36 (30)
 PTPN11 2 (2)* 6 (13) 25 (21)
 SRSF2 20 (21) 3 (8) 9 (8)
 SF3B1 9 (9) 4 (9) 1 (0.8)
 TP53 15 (16)* 1 (2) 0 (0)
Mutation count, median (range) 2 (0-8) 2 (1-7) 4 (1-8)§
Abnormal karyotype, n (%) 57 (61)* 5 (12) 18 (16)
*

IDH1 and IDH2 are grouped for the analysis comparing NPM1+ MN with NPM1+ AML (Fisher's exact test).

KRAS and NRAS are grouped for the analysis comparing NPM1+ MN with NPM1+ AML (Fisher's exact test).

Significantly different compared with NPM1+ MN (Fisher's exact test).

§

P < .05 for difference compared with NPM1+ MN (Mann-Whitney U test).